GNI Group Ltd GNIIF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- $38.80–38.80
- Bid/Ask
- $5.58 / $173.69
- Market Cap
- —
- Volume/Avg
- 31,503 / 31,503
Key Statistics
- Price/Earnings (Normalized)
- 915.93
- Price/Sales
- 12.02
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- < 0.01%
Company Profile
GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for the treatment of cancer and inflammatory diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 865
- Website
- http://www.gnipharma.com
Comparables
Valuation
|
Metric
|
GNIIF
|
190A
|
4565
|
|---|---|---|---|
Price/Earnings (Normalized) | 915.93 | — | — |
Price/Book Value | 5.34 | — | 1.70 |
Price/Sales | 12.02 | — | 4.84 |
Price/Cash Flow | 87.68 | — | — |
Price/Earnings
GNIIF
190A
4565
Financial Strength
|
Metric
|
GNIIF
|
190A
|
4565
|
|---|---|---|---|
Quick Ratio | 2.42 | 23.49 | 3.85 |
Current Ratio | 2.83 | 24.76 | 4.11 |
Interest Coverage | 4.64 | — | −3.39 |
Quick Ratio
GNIIF
190A
4565
Profitability
|
Metric
|
GNIIF
|
190A
|
4565
|
|---|---|---|---|
Return on Assets (Normalized) | 9.32% | −52.00% | −5.96% |
Return on Equity (Normalized) | 17.77% | −55.58% | −13.30% |
Return on Invested Capital (Normalized) | 16.91% | −55.58% | −5.85% |
Return on Assets
GNIIF
190A
4565
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Gsvpzqqykn | Pgp | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Tmrpxjyz | Hfrnfs | $119.6 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Yhmlssq | Vsxvjx | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ztvbzwyt | Ltghjs | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Fhzxcbj | Xkj | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Mtzcvcn | Nvsr | $28.0 Bil | |||
| Moderna Inc
MRNA
| Wfbpcpgxm | Lzyx | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Rpqckswdf | Klvgm | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Cgtjmxgv | Ystlrn | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Tfhnxrdnl | Wzvlr | $12.6 Bil |
United States